These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 22759327)
1. Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study. Kudo T; Fujinami H; Ando T; Nishikawa J; Ogawa K; Hosokawa A; Orihara T; Murakami J; Takahara T; Sugiyama T Helicobacter; 2012 Aug; 17(4):277-81. PubMed ID: 22759327 [TBL] [Abstract][Full Text] [Related]
2. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. Kim N; Park SH; Seo GS; Lee SW; Kim JW; Lee KJ; Shin WC; Kim TN; Park MI; Park JJ; Hong SJ; Shim KN; Kim SW; Shin YW; Chang YW; Chun HJ; Lee OJ; Jeon WJ; Park CG; Cho CM; Park CH; Won SY; Lee GH; Park KS; Shin JE; Kim HU; Park JY; Chae HS; Song GA; Kim JG; Yoon BC; Seol S; Jung HC; Chung IS Helicobacter; 2008 Dec; 13(6):542-9. PubMed ID: 19166420 [TBL] [Abstract][Full Text] [Related]
3. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Matsuhisa T; Kawai T; Masaoka T; Suzuki H; Ito M; Kawamura Y; Tokunaga K; Suzuki M; Mine T; Takahashi S; Sakaki N Helicobacter; 2006 Jun; 11(3):152-8. PubMed ID: 16684262 [TBL] [Abstract][Full Text] [Related]
5. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area. Asaoka D; Nagahara A; Matsuhisa T; Takahashi S; Tokunaga K; Kawai T; Kawakami K; Suzuki H; Suzuki M; Nishizawa T; Kurihara N; Ito M; Sasaki H; Omata F; Mizuno S; Torii A; Ohkusa T; Mine T; Sakaki N Helicobacter; 2013 Dec; 18(6):468-72. PubMed ID: 23773231 [TBL] [Abstract][Full Text] [Related]
6. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients. Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716 [TBL] [Abstract][Full Text] [Related]
7. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111 [TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140 [TBL] [Abstract][Full Text] [Related]
9. A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey. Sezgin O; Altintaş E; Nayir E; Uçbilek E Helicobacter; 2007 Dec; 12(6):629-32. PubMed ID: 18001405 [TBL] [Abstract][Full Text] [Related]
10. Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan. Fukuda S; Shimoyama T; Tanaka M; Nakasato F; Fukushi M; Munakata A Jpn J Infect Dis; 2006 Dec; 59(6):367-9. PubMed ID: 17186954 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. Murakami K; Sato R; Okimoto T; Watanabe K; Nasu M; Fujioka T; Kodama M; Abe T; Sato S; Arita T J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):262-7. PubMed ID: 16460484 [TBL] [Abstract][Full Text] [Related]
12. Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen. Nagahara A; Miwa H; Kawabe M; Kurosawa A; Asaoka D; Hojo M; Iijima K; Terai T; Ohkusa T; Miyazaki A; Sato N J Gastroenterol; 2004 Nov; 39(11):1051-5. PubMed ID: 15580397 [TBL] [Abstract][Full Text] [Related]
13. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure. Ueki N; Miyake K; Kusunoki M; Shindo T; Kawagoe T; Futagami S; Tsukui T; Inagaki H; Sakamoto C Helicobacter; 2009 Apr; 14(2):91-9. PubMed ID: 19298336 [TBL] [Abstract][Full Text] [Related]
14. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Kongchayanun C; Vilaichone RK; Pornthisarn B; Amornsawadwattana S; Mahachai V Helicobacter; 2012 Aug; 17(4):282-5. PubMed ID: 22759328 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. Shimoyama T; Fukuda S; Mikami T; Fukushi M; Munakata A J Gastroenterol; 2004 Oct; 39(10):927-30. PubMed ID: 15549444 [TBL] [Abstract][Full Text] [Related]
16. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Lim JH; Lee DH; Choi C; Lee ST; Kim N; Jeong SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Jo HJ; Jang ES; Song Is; Jung HC Helicobacter; 2013 Jun; 18(3):180-6. PubMed ID: 23305083 [TBL] [Abstract][Full Text] [Related]
18. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. Isomoto H; Inoue K; Furusu H; Nishiyama H; Shikuwa S; Omagari K; Mizuta Y; Murase K; Murata I; Kohno S Helicobacter; 2003 Apr; 8(2):111-9. PubMed ID: 12662378 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. Murakami K; Okimoto T; Kodama M; Sato R; Watanabe K; Fujioka T J Clin Gastroenterol; 2008 Feb; 42(2):139-42. PubMed ID: 18209581 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy. Togawa J; Inamori M; Fujisawa N; Takahashi H; Yoneda M; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H Hepatogastroenterology; 2005; 52(62):645-8. PubMed ID: 15816496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]